Almost half of UK doctors would not use generative artificial intelligence (GenAI) to treat patients, although there is greater willingness to use it for diagnostic purposes.
Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland.
Novartis' targeted Factor B inhibitor Fabhalta – the first oral monotherapy for rare disease paroxysmal nocturnal haemoglobinuria (PNH) – has been cleared by NICE for use by the NHS in Engl
A digital version of the NHS Health Check offered to older people in the UK will be piloted in some areas of England early next year, according to the government.
The £400 million ($529 million) investment programme pledged as part of the new voluntary system of rebates paid by pharma companies in the UK has been announced and will focus mainly on su
The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after an EU committee turned it down on the grounds that its modest efficacy did not outw
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.